Taysha Gene Therapies Gross Profit 2020-2026 | TSHA

Taysha Gene Therapies gross profit from 2020 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Taysha Gene Therapies Annual Gross Profit
(Millions of US $)
2025 $10
2024 $8
2023 $15
2022 $3
Taysha Gene Therapies Quarterly Gross Profit
(Millions of US $)
2025-12-31 $5
2025-06-30 $2
2025-03-31 $2
2024-12-31 $2
2024-09-30 $2
2024-06-30 $1
2024-03-31 $3
2023-12-31 $4
2023-09-30 $5
2023-06-30 $2
2023-03-31 $5
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.652B $0.010B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $44.899B 17.67
BridgeBio Pharma (BBIO) United States $13.352B 0.00
Dr Reddy's Laboratories (RDY) India $9.749B 24.85
Aspen Pharmacare (APNHY) South Africa $4.248B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.409B 20.18
Bausch Health Cos (BHC) Canada $2.129B 1.33
Personalis (PSNL) United States $1.687B 0.00
Amphastar Pharmaceuticals (AMPH) United States $1.019B 9.58
Assembly Biosciences (ASMB) United States $0.519B 24.98
Sol-Gel Technologies (SLGL) Israel $0.178B 0.00
Metagenomi Therapeutics (MGX) United States $0.043B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00